OptiNose, Inc.
DelistedCIK 1494650fmd_0X1V9E5Q25Q5JNK1SACX973ZV3Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2015 to Mar 31, 2025, 38 periods
| Line item | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | 0 | 7 | 35 | 49 | 75 | 76 | 71 | 78 |
| Cost of revenue | – | – | 0 | 2 | 5 | 8 | 9 | 9 | 9 | 7 |
| Gross profit | – | – | 0 | 5 | 29 | 42 | 66 | 67 | 62 | 71 |
| Research and development | 22 | 15 | 17 | 10 | 21 | 23 | 25 | 15 | 5 | 4 |
| Selling, general and administrative | 6 | 7 | 32 | 96 | 104 | 105 | 107 | 108 | 80 | 83 |
| Total operating expenses | 28 | 22 | 49 | 106 | – | – | – | – | – | – |
| Operating income | (28) | 25 | (49) | (100) | (96) | (87) | (66) | (56) | (23) | (16) |
| Interest expense | 1 | 4 | 1 | 9 | 10 | 13 | 16 | 17 | 20 | 20 |
| Interest and investment income | 0 | 0 | 0 | 2 | 2 | 0 | 0 | 1 | 3 | 3 |
| Income before taxes | – | 23 | (49) | (107) | (110) | (100) | (82) | (75) | (35) | (22) |
| Income tax expense | – | – | 0 | – | – | – | – | – | – | – |
| Net income from continuing operations | – | – | (49) | – | – | – | – | – | – | – |
| Net income | (28) | 23 | (49) | (107) | (110) | (100) | (82) | (75) | (35) | (22) |
| Net income to common shareholders | (40) | 9 | (62) | (107) | – | – | – | – | – | – |